Sanofi will seek to draw from its experience with other drugs that treat rare blood disorders as it launches Enjaymo (sutimlimab-jome) as the sole drug approved to treat cold agglutinin disease (CAD), and the latest in the company’s efforts to build a rare blood disease franchise.
Enjaymo received US Food and Drug Administration approval on 4 February to decrease the need for red blood cell transfusion due to hemolysis in CAD patients
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
